Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial
October 7, 2026 — Quantum BioPharma partners with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS, a novel neuroprotective MS treatment.
Curated Health Wellness News
NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
VERAXA Biotech Advances FDA-Aligned Methods to Reduce Animal Testing
October 7, 2026 — VERAXA Biotech (NASDAQ: VRXA) updates on FDA-aligned NAMs to cut animal testing in cancer research, advancing BiTAC T cell engagers and antibody-drug conjugates.
SS Innovations Advances Telerobotic Surgery with 195 Remote Procedures
October 7, 2026 — SS Innovations advances telerobotic surgery with 195 remote procedures using SSi Mantra. The company expands to 12 countries and seeks FDA clearance.
Lantern Pharma Gets Taiwan IRB Nod for Phase 2 HARMONIC Trial
October 7, 2026 — Lantern Pharma receives Taiwan IRB approval for Phase 2 HARMONIC trial of LP-300 in EGFR L858R lung cancer, expanding clinical development.
Quantum BioPharma Partners with Thermo Fisher for Phase 2 MS Trial
October 7, 2026 — Quantum BioPharma signs Study Start-Up Agreement with Thermo Fisher for Phase 2 trial of Lucid-MS, a novel MS therapy targeting demyelination.
VERAXA Biotech Advances FDA-Aligned NAMs to Cut Animal Testing
October 7, 2026 — VERAXA Biotech (NASDAQ: VRXA) advances FDA-aligned New Approach Methodologies to accelerate cancer therapy development, reduce animal testing, and cut costs.
Dutchess Orthodontics Sets Standard for Braces in Hopewell Junction
October 7, 2026 — Dutchess Orthodontics outlines key criteria for choosing braces for kids, teens, and adults in Hopewell Junction NY, offering braces, clear aligners, and free consultations.
Quantum BioPharma Taps Thermo Fisher for Phase 2 MS Trial
October 7, 2026 — Quantum BioPharma partners with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a novel MS therapy targeting myelin repair, offering hope for progressive MS patients.
XORTX Therapeutics Targets $700M Gout Market with XORLO
October 7, 2026 — XORTX Therapeutics advances XORLO, a novel gout treatment, with manufacturing and FDA plans. Could capture $700M market as gout cases rise globally.
C60 Power Celebrates National C60 Day with Sale and Education
October 7, 2026 — C60 Power celebrates National C60 Day on October 9 with a 20% storewide sale, educational events, and community stories. Learn about Carbon 60 research and products.
Braces Now in Buford Offers Braces & Invisalign for All Ages
October 7, 2026 — Braces Now in Buford, GA offers braces and Invisalign for children, teens, and adults. Experience personalized orthodontic care with advanced digital technology.
Quantum BioPharma Partners with Thermo Fisher for Lucid-MS Phase 2 Trial
October 6, 2026 — Quantum BioPharma partners with Thermo Fisher to launch Phase 2 trial of Lucid-MS for multiple sclerosis, a first-in-class neuroprotective treatment targeting PAD2.
Telomir Pharma Raises $5.6M for TNBC Trial
October 6, 2026 — Telomir Pharmaceuticals (NASDAQ: TELO) secures $5.6M PIPE financing to advance Telomir-Zn into Phase 1/2 trials for triple-negative breast cancer. FDA IND cleared.
NanoViricides to Present at NIBA Conference, Advancing Broad-Spectrum Antiviral NV-387
October 6, 2026 — NanoViricides to present at NIBA 153rd Investment Conference on Oct 7, 2026. Lead drug NV-387 in Phase 2 trials for Ebola and Mpox, with plans for measles and other viruses.
Quantum BioPharma Advances Phase 2 MS Trial with Thermo Fisher Partnership
October 6, 2026 — Quantum BioPharma partners with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a novel multiple sclerosis treatment targeting PAD2 to prevent myelin degradation.
Skull's Hidden Lymph Nodes May Boost Brain Immunity, Study Finds
October 6, 2026 — WashU Medicine study finds lymph node-like structures in skull bone marrow, suggesting a local brain immune defense. Could lead to new brain cancer therapies.
Okogen Gets CDSCO Nod for Treyegen™ Phase 1/2 Conjunctivitis Study
October 6, 2026 — Okogen wins CDSCO authorization for EMERALD Phase 1/2 trial of Treyegen™ (OKG-0303) in acute infectious conjunctivitis, enrolling 300+ patients in India.
Kairos Pharma's ENV-105 Combo Triples PFS in Prostate Cancer Trial
October 6, 2026 — Kairos Pharma's ENV-105 plus apalutamide shows 17.7-month PFS in prostate cancer trial, a significant improvement over apalutamide alone. Interim Phase 2 data.
AXIM Submits 510(k) for Rapid Dry Eye Test, Eyes CLIA Waiver
October 6, 2026 — AXIM Biotechnologies submits 510(k) to FDA for a rapid, point-of-care dry eye test measuring lactoferrin. Plans CLIA waiver to expand access in eye care offices.
UNLOCKD and NEXT10 Join Forces to Build Scalable Wellness Platform
October 6, 2026 — UNLOCKD Inc. and NEXT10, Inc. partner to build a scalable health, wellness, and longevity platform, targeting $65-$95M revenue and 62 wellness centers.